---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009175"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:12:08.198108+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio prioritizes ABI-4334, pauses ABI-H3733 on chronic toxicology finding; Q4 2022 net loss $93.1M

## Summary
- Phase 1a for ABI-4334 complete for single-dose and 100mg multiple-dose; half-life supports once-daily dosing; 200mg data expected April.
- Phase 1b for ABI-H3733: all 7 HBeAg-negative patients achieved HBV DNA below LLOQ by day 21; chronic toxicology in one species halted program.
- Net loss $93.1M ($1.92/share) for FY2022 vs $129.9M ($3.00/share) in 2021; cash $91.6M as of Dec 31, 2022, funding into mid-2024.
- Second development candidate nomination expected in 2023; IND/CTA for herpesvirus candidate ABI-5366 planned for first half 2024.
- CEO Jason Okazaki appointed as previously reported; no new leadership change in this filing.

## SEC filing metadata
- accession: 0000950170-23-009175
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017023009175/0000950170-23-009175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017023009175/asmb-20230322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009175
- JSON: https://secwatch.observer/filing/0000950170-23-009175.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009175.txt

## Key facts
- Earnings Releases
  ASSEMBLY BIOSCIENCES, INC. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 22, 2023, Assembly Biosciences, Inc. (the "Company") issued a press release (the "Press Release") announcing its financial results for the quarter and year ended December 31, 2022 and recent corporate highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000095017023009175/0000950170-23-009175-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.